Close Menu

NEW YORK (GenomeWeb) – Drug and diagnostics giant Roche and proteomics firm Biognosys have completed a study indicating that data-independent acquisition (DIA) mass spec is suitable for use in clinical trials.

The companies presented data at the Mass Spectrometry Applications to the Clinical Lab (MSACL) annual conference this month from a mock clinical trial in which Roche used DIA mass spec to collect proteomic data on 30 colorectal cancer specimens.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.